Toward clinical-scale nonviral gene-edited CAR-NK cells for cell therapy

Improving the accessibility and effectiveness of cell therapies is essential to meet the growing demand for cancer treatments. Engineered natural killer (NK) cells represent a promising modality, offering safety, effectiveness, and the possibility of allogeneic use. This article highlights gene editing techniques such as CRISPR-Cas9 for enhancement of NK cell functionality, and explores nonviral transfection methods and scalable manufacturing processes. Additionally, a case study on anti-Meso3 CAR-NK cells targeting ovarian cancer cell line is explored, showcasing the enhanced efficacy of engineered CAR-NK cells for killing cancer cells and their potential for clinical scale applications.